久久人做人妻一区二区三区-日本一本二本三本不卡区-亚洲一区二区三区99区-下面好多水想要被插视频

類器官CHIR-99021

簡要描述:類器官CHIR-99021
類器官(Organoids)是指將成體干細胞或多能干細胞在體外三維培養(yǎng)形成的具有一定空間結構的組織類似物。類器官在組織結構、細胞類型、自我更新能力和功能等方面與來源組織高度一致,從而在發(fā)育生物學、疾病造模、精準醫(yī)學、藥物研發(fā)、基因和細胞療法、感染和免疫以及再生醫(yī)學等生物醫(yī)學的多個領域展現出*的優(yōu)勢。

  • 產品型號:
  • 廠商性質:代理商
  • 更新時間:2025-06-26
  • 訪  問  量:942

詳細介紹

品牌其他品牌供貨周期現貨

類器官CHIR-99021

類器官(Organoids)是指將成體干細胞或多能干細胞在體外三維培養(yǎng)形成的具有一定空間結構的組織類似物。類器官在組織結構、細胞類型、自我更新能力和功能等方面與來源組織高度一致,從而在發(fā)育生物學、疾病造模、精準醫(yī)學、藥物研發(fā)、基因和細胞療法、感染和免疫以及再生醫(yī)學等生物醫(yī)學的多個領域展現出*的優(yōu)勢。

產品介紹
DESCRIPTION

BackgroundCHIR-99021 is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy[1][2][3].
Alias

Laduviglusib; CT99021

 
M. W t465.34
FormulaC22H18Cl2N8
CAS No252917-06-9
StoragePowder-20°C3 years
4°C2 years                               C22H18Cl2N8
In solvent-80°C6 months         
-20°C1 month
SolubilityDMSO       16.67 mg/mL(35.82 mM)

H2O< 0.1 mg/mL(insoluble)

BIOLOGICAL ALTIVITY
In Vitro  
CHIR-99021 inhibits human GSK-3β with Ki values of 9.8 nM[1]. Laduviglusib is a small organic molecule that inhibits GSK3α and GSK3β by competing for their ATP-binding sites.In vitro kinase assays reveal that Laduviglusib specifically inhibits GSK3β (IC50=~5 nM) and GSK3α (IC50=~10 nM), with little effect on other kinases[4]. In the presence of Laduviglusib the viability of the ES-D3 cells is reduced by 24.7% at 2.5 μM, 56.3% at 5 μM, 61.9% at 7.5 μM and 69.2% at 10 μM Laduviglusib with an IC50 of 4.9 mm[2].
In Vivo
In ZDF rats, a single oral dose of Laduviglusib (16 mg/kg or 48 mg/kg) rapidly lowers plasma glucose, with a maximal reduction of nearly 150 mg/dl 3-4 h after administration[1]. Laduviglusib (2 mg/kg) given once, 4 h before irradiation, significantly improves survival after 14.5 Gy abdominal irradiation (ABI). Laduviglusib treatment significantly blocks crypt apoptosis and accumulation of p-H2AX+ cells, and improves crypt regeneration and villus height. Laduviglusib treatment increases Lgr5+ cell survival by blocking apoptosis, and effectively prevents the reduction of Olfm4, Lgr5 and CD44 as early as 4 h[5].

類器官CHIR-99021

產品咨詢

留言框

  • 產品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結果(填寫阿拉伯數字),如:三加四=7
掃碼關注 掃一掃,關注微信
版權所有©2025 普邁精醫(yī)科技(北京)有限公司    備案號:京ICP備18047241號-3

化工儀器網    管理登陸    sitemap.xml